X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
https://www.globenewswire.com/news-release/2024/01/31/2820708/0/en/Sandoz-launches-first-and-only-biosimilar-for-multiple-sclerosis-Tyruko-natalizumab-in-Germany.html
https://www.ema.europa.eu/en/documents/overview/tyruko-epar-medicine-overview_en.pdf
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125104
https://www.ema.europa.eu/en/documents/overview/tyruko-epar-medicine-overview_en.pdf
https://www.financialexpress.com/healthcare/pharma-healthcare/sandoz-gets-european-commission-approval-for-biosimilar-for-multiple-sclerosis-in-europe/3254934/
https://www.fda.gov/news-events/press-announcements/fda-approves-first-biosimilar-treat-multiple-sclerosis
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761322
https://www.globenewswire.com/news-release/2023/07/24/2709225/0/en/Sandoz-receives-positive-CHMP-opinion-for-multiple-sclerosis-biosimilar-natalizumab.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125104
https://www.nasdaq.com/articles/genentech-sues-biogen-for-royalties-on-blockbuster-ms-drug
https://endpts.com/unsealed-documents-detail-biogens-fight-against-sandoz-tysabri-biosimilar/
https://www.biopharmadive.com/news/novartis-tysabri-biosimilar-biogen-multiple-sclerosis/628026/
https://www.globenewswire.com/news-release/2022/07/25/2484755/0/en/Applications-for-proposed-first-of-a-kind-multiple-sclerosis-biosimilar-natalizumab-accepted-by-US-FDA-and-EMA.html
https://www.fiercepharma.com/pharma/biogen-pays-900m-resolve-ms-drugs-doctor-kickback-whistleblower-suit-competition-mounts
https://pharmaphorum.com/news/polpharma-in-pole-position-for-biosimilar-tysabri-in-europe/
https://www.b3cnewswire.com/202207152374/polpharma-biologics-announces-ema-acceptance-of-marketing-authorization-application-for-proposed-biosimilar-natalizumab.html
https://www.fiercepharma.com/pharma/patent-loss-for-tysabri-europe-add-one-more-item-to-biogen-s-long-list-concerns
https://endpts.com/biogen-wont-explain-why-fda-slapped-down-their-bid-for-new-tysabri-formulation/
https://endpts.com/biogen-wont-explain-why-fda-slapped-down-their-bid-for-new-tysabri-formulation/
https://www.globenewswire.com/news-release/2021/04/28/2219162/0/en/Biogen-Provides-Regulatory-Update-on-the-Supplemental-Biologic-License-Application-sBLA-for-Subcutaneous-Administration-of-TYSABRI-natalizumab.html
http://www.pharmatimes.com/news/new_subcutaneous_formulation_of_tysabri_approved_in_uk_1367221
http://www.pharmatimes.com/news/new_subcutaneous_formulation_of_tysabri_approved_in_uk_1367221
http://www.pharmatimes.com/news/eu_nod_for_new_formulation_of_biogens_tysabri_1366604
https://www.thepharmaletter.com/in-brief/brief-eu-green-light-for-new-subcutaneous-tysabri-for-ms
https://www.biopharmadive.com/news/abbvie-biogen-drug-price-increases-2021/592768/
https://www.biopharmadive.com/news/abbvie-biogen-drug-price-increases-2021/592768/
https://www.rte.ie/news/business/2020/1104/1175852-perrigo-court/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125104
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125104
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125104
https://www.centerforbiosimilars.com/news/clinical-studies-to-begin-for-natalizumab-aflibercept-and-bevacizumab-biosimilars
https://www.reuters.com/article/us-novartis-ms/novartiss-sandoz-licenses-proposed-multiple-sclerosis-biosimilar-idUSKCN1VO0GQ?feedType=RSS&feedName=healthNews
https://seekingalpha.com/news/3496237-polpharma-bio-teams-up-sandoz-to-commercialize-tysabri-biosimilar
https://pharmaphorum.com/news/novartis-strikes-marketing-deal-for-polpharmas-potential-tysabri-biosimilar/
https://polpharmabiologics.com/en/knowledge/latest-news/article/polpharma-biologics-announces-global-commercialization-deal-for-biosimilar-natalizumab-a-key-multiple-sclerosis-medicine#:~:text=PL%20EN-,Polpharma%20Biologics%20announces%20global%20commercialization%20deal%20for%20biosimilar,a%20key%20multiple%20sclerosis%20medicine&text=Under%20this%20agreement%2C%20Polpharma%20Biologics,supply%20of%20the%20collaboration%20biosimilar.
https://www.fiercepharma.com/pharma/roche-genentech-s-ocrevus-continues-winning-streak-after-nice-flip-flops-initial-guidance
https://www.fiercepharma.com/pharma/perrigo-knocked-for-873m-unpaid-royalties-from-tysabri-sale
https://www.reuters.com/article/us-biogen-results/biogen-beats-estimates-on-multiple-sclerosis-drugs-sales-idUSKCN1PN1BV
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125104
https://www.fiercepharma.com/pharma/perrigo-s-1-9b-tysabri-irish-tax-bill-adds-lingering-negative-analyst
Market Place
Share 
